



## VantagePoint – BizInt Smart Charts Edition

Orange, California - 1 June 2012 (Update)

BizInt Solutions, Inc. is pleased to announce an agreement with Search Technology, Inc. to develop and market a custom version of VantagePoint for use by BizInt Smart Charts customers.

VantagePoint – BizInt Smart Charts Edition will import files exported by BizInt Smart Charts for Drug Pipelines or BizInt Smart Charts for Patents, using a custom version of the new XML Smart Data Exchange format. BizInt Smart Charts users can apply data cleaning and user-managed thesaurus tools in VantagePoint and then export cleaned and normalized fields back to BizInt Smart Charts.

"I am very excited by the potential of VantagePoint to offer BizInt Smart Charts users powerful features for normalizing and enhancing data in multi-database reports," said Diane Webb, President, BizInt Solutions, Inc. "Especially used in conjunction with our new BizInt Smart Charts Reference Rows utility, VantagePoint will help our users create truly meaningful multi-database reports, with consistent values across databases."

VantagePoint – BizInt Smart Charts Edition will contain VantagePoint's core analytics suite including market-leading Data Cleanup, Thesaurus, Record Classifications, My Keywords, and interactive analytical visualizations. Data exchange between the two tools will be simplified to make it easy to move data back and forth, allowing the user to concentrate on analysis and reporting, rather than managing data flow.

"VantagePoint and BizInt Smart Charts are an ideal pair for the Information Professional – powerful analytics with flexible data integration and reporting," said Paul Frey, President, Search Technology, Inc., developers of VantagePoint. "We are delighted to work with BizInt Solutions to bring this streamlined solution to the Drug Pipeline and Patent information markets."

VantagePoint – BizInt Smart Charts Edition will be sold by BizInt Solutions as part of a BizInt Smart Charts license. Annual license pricing will be \$3000 for the first user and \$1600 for additional users in the same license. The expected release date is Summer 2012.

## **Contact:**

Diane Webb BizInt Solutions, Inc. 1.714.289.1000 products@bizcharts.com http://www.bizcharts.com

Paul Frey Search Technology, Inc. 1.770.441.1457 VantagePoint@searchtech.com http://www.TheVantagePoint.com

SOFTWARE FOR BUSINESS INTELLIGENCE

## Using BizInt Smart Charts and VantagePoint 7.1 with the XML Smart Data Exchange

BizInt Smart Charts and VantagePoint 7.1 users can use the XML Smart Data Exchange format to export data to VantagePoint and then reimport analyzed data in BizInt Smart Charts.

- Create your report in BizInt Smart Charts for Patents or BizInt Smart Charts for Drug Pipelines and then export using the "XML-Smart Data Exchange" option under File | Export. Keep the BizInt Smart Charts file open for Step 7 below.
- In VantagePoint, import the .xml file using the Import XML Smart Data Exchange icon on the VP toolbar.
- Use the data cleaning and user-managed thesaurus tools in VantagePoint to create new fields.
- Export the new fields back to BizInt Smart Chart by selecting the Export XML Smart Data Exchange icon on the VantagePoint toolbar.
- In step 2 of the VantagePoint Export Wizard, select "<<Remove All", then add the "recordID" and the VP created fields you wish to export. Do not export all fields or you will end up with duplicate fields in Smart Charts.
- In step 3 of the VantagePoint Export Wizard, select which BizInt Smart Charts product you are exporting to, the "Launch Application" radio button, and Finish.

BizInt Smart Charts will ask you to select the chart to which you wish to add the data. The fields you exported from VantagePoint will be added to the chart as "User" fields.

|      | Trial Title   | Database                         | Phase   | Phase<br>(Normalize<br>d) | Sponsor(s)  | Trial Status                       | Trial Status (Normalized)  Planned  Active, Not Recruiting |  |
|------|---|----------------------------------|---------|---------------------------|---|------------------------------------|--|--|
| 6 D  | PP4 Inhibitor in the Hospital   | ClinicalTrials.Gov               | Phase 4 | Phase 4 🗸                 | Emory University/<br>Merck                            | Not yet recruiting                 |  |  |
| 6 D  | PP-IV Inpatient Trial   | ClinicalTrials.Gov               | Phase 4 | Phase 4                   | Emory University<br>Merck                             | Active, not recruiting             |  |  |
| .3 D | andomized Controlled Study of<br>PP4 Inhibitor (Sitagliptin) Therapy in<br>le Inpatient Management of Patients<br>Jith Type 2 Diabetes. | Citeline TrialTrove              | IV 🗸    | Phase 4                   | Emory University<br>Hospital - Atlanta<br>Merck & Co. | Planned 🗸                          | Planned 🗸  |  |
| 4 In | andomized Controlled Study of DPP4<br>hibitor (Sitagliptin) Therapy in the<br>patient Management of Patients With<br>ype 2 Diabetes.    | Adis Clinical Trials<br>Database | IV      | Phase 4                   | Merck & Co  | Active, no<br>longer<br>recruiting | Active, Not<br>Recruiting                                  |  |
| 1 In | hanges in Bone Turnover With<br>creased Incretin Hormone<br>xposure   | ClinicalTrials.Gov               | Phase 4 | Phase 4                   | University of Alabama at Birmingham                   | Recruiting                         | Open,<br>Recruiting  |  |
| 2 In | hanges in Bone Turnover With<br>creased Incretin Hormone<br>xposure (UAB Diabetes Research  | Citeline TrialTrove              | IV 🗸    | Phase 4                   | University of<br>Alabama,<br>Birmingham               | Open 🗸                             | Open, /<br>Recruiting                                      |  |

Database

Patent Assignee

Title

|    | #Records | # Instances | Highest Phase (1)       |  |
|----|----------|-------------|-------------------------|--|
| 1  | 131      | 131         | Preclinical             |  |
| 2  | 90       | 90          | Biological Testing      |  |
| 3  | 64       | 64          | No Development Reported |  |
| 4  | 57       | 57          | Phase 2                 |  |
| 5  | 56       | 56          | Phase 1                 |  |
| 6  | 36       | 36          | Discontinued            |  |
| 7  | 29       | 29          | Phase 3                 |  |
| 8  | 23       | 23          | Launched                |  |
| 9  | 9        | 9           | Phase 1/2               |  |
| 10 | 2        | 2           | Technology              |  |
| 11 | 1        | 1           | Clinicals               |  |
| 12 | 1        | 1           | Preregistration         |  |

Fields to Export

Next>

Order: Move Selected Fields...

Up

Down

Finish

nventor(s) - Normalized (Vantac

Export Wizard (Select Fields)

Select and Order Fields to Expor Available Fields

> Add All >> Add >

< Remove

<< Remove All

< Back

Inventor(s)

an Commercial Intro

copyright database databaseLabel Highest Phase Indications

Indications
Licensee
Mechanism of Action
Originator
Product
recordURL
Synonyms
Therapeutic Activity
updateDate

Export Editable Notes

Cancel

Export Record Classifications

Highlighted in yellow are columns created by VantagePoint normalized phases and trial status fields in a clinical trials chart (above) and normalized Assignees (companies only) and Inventors in a patents chart (at right).

Feasibility Study)

97

Changes in Bone Turnover With

| ı  | Increased Incretin Hormone Exposi  |   | ritte  | Database                        | Patent Assignee  | Only (Vantage Point)              | inventor(s)  | Point)   |
|--|--|---|--|---------------------------------|--|-----------------------------------|--|--|
|  | (UAB Diabetes Research and Train<br>Center Pilot and Feasibility Study).                             |   | Mousetrap  | PatBase                         | RECKITT BENCKISER AU PTY LTD<br>RECKITT BENCKISER UK LTD<br>RODGERS BRENDYN MURRAY<br>WATSON DUNCAN MCLEOD<br>WEST JEFFREY | RECKITT BENCKISER                 | RODGERS BRENDYN M<br>RODGERS BRENDYN MURRAY<br>WATSON DUNCAN M<br>WATSON DUNCAN MC LEOD<br>WATSON DUNCAN MCLEO<br>WEST JEFFREY | RODGERS BRENDYN MURRAY<br>WATSON, Duncan, McLeod<br>WEST, Jeffrey<br>WATSON DUNCAN MCLEO |
| e columns c<br>VantagePoi<br>rmalized ph | ghlighted in yellow<br>columns created<br>VantagePoint –<br>rmalized phases<br>I trial status fields | 2 | Mouse trap used at home has<br>enclosure which is provided<br>with top and base having<br>aperture and indentation that<br>can be aligned to open<br>enclosure for entry of mouse,<br>such that contra-rotation of<br>top relative to base is enabled<br>to trap mouse | Thomson<br>Innovation +<br>DWPI | RECKITT BENCKISER<br>RECKITT BENCKISER AUSTRALIA<br>PTY LTD<br>RECKITT BENCKISER UK LTD                                    | RECKITT BENCKISER                 | RODGERS, Brendyn, Murray<br>WATSON, Duncan, McLeod<br>WEST, Jeffrey  | RODGERS BRENDYN MURRAY<br>WATSON, Duncan, McLeod<br>WEST, Jeffrey                        |
|  | a clinical trials<br>art (above) and   | 3 | Portable electrical mouse trap   | TotalPatent                     | JORDAN, SR. CHARLES  |                                   | Charles Jordan, Sr.  | Jordan, Sr., Charles   |
| rmaliz<br>ompar<br>⁄entor                | malized Assignees  | 4 | Safety disposable mouse trap   | FAMPAT                          | CRIDER JACK B SR<br>CRISPENS JACQUELYN R   |                                   | CRISPENS JACQUELYN R<br>CRIDER JACK B SR   | CRIDER, Jack B. Sr.<br>Crispens, Jacquelyn, R.   |
|  | mpanies only) and entors in a patents  | 5 | Mousetrap  | PatBase                         | RECKITT BENCKISER NV<br>RECKITT BENCKISER AU PTY LTD   | RECKITT BENCKISER                 | WATSON DUNCAN MCLEOD<br>WATSON DUNCAN M<br>RODGERS BRENDYN MURRAY<br>RODGERS BRENDYN M   | RODGERS BRENDYN MURRAY<br>WATSON, Duncan, McLeod   |
|  | art (at right).  | 6 | Mousetrap for use in garden,<br>has catch container designed<br>as bottle and including pivot<br>that is twistably supported on<br>support plate of support rack,<br>where swivel axis of<br>container runs through center<br>of gravity of container                  | TotalPatent                     | Wenk, Karl-Heinz, 58455 Witten, DE   |                                   | Wenk, Karl-Heinz, 58455 Witten,<br>DE  | WENK KARL HEINZ  |
|  |  | 7 | High voltage electronic rat<br>eradication equipment   | FAMPAT                          | XIANGMING HIGH SCHOOL<br>SHANGHAI  | SHANGHAI XIANGMING<br>HIGH SCHOOL | HUANG ZENGXIN YAN  | HUANG ZENGXIN YAN  |

Assignees - Companies

Only (Vantage Point)